Request Sample Inquiry
Diabetic Macular Edema Market

Diabetic Macular Edema Market

Diabetic Macular Edema Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

166

Base Year:

2023

Date

Aug - 2024

Format:

PDF XLS PPT

Report Code:

VMR-VMR-2021-0525

Segments Covered
  • By Indication Type By Indication Type diffuse diabetic macular edema, focal diabetic macular edema
  • By Treatment Type By Treatment Type anti-VEGF, corticosteroids, laser photocoagulation therapy, other off-label drugs
  • By Power Consumption By Power Consumption intravitreal injections, intravitreal implants
  • By End User By End User hospitals, specialty clinics, order pharmacies
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 4.35 Billion
Revenue 2032Revenue 2032: USD 5.61 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 3.2%
Fastest Growing Region Fastest Growing Region (2024 - 2032) XX
Largest Region Largest Region (2023): XX
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
Diabetic Macular Edema Market Share

Key Insights

The global Diabetic Macular Edema Market is valued at USD 4.35 Billion in 2023 and is projected to reach a value of USD 5.61 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 3.2% between 2024 and 2032.

Overview and Description

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula part of the retina that controls our most detailed vision abilities, due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy.

The Global Diabetic Macular Edema Market is segmented based on products, applications, regions, and countries. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. All the segments have been analyzed based on present and future trends. The research study provides complete assessment of the market on the basis of competition, drivers, restraints, opportunities, trends, and industry-authenticated data. The market is estimated from 2018 to 2022 with forecast from 2023 to 2032.

Diabetic Macular Edema Market Size, 2023 To 2032 (USD Billion)

AI (GPT) is here !!! Ask questions about Diabetic Macular Edema Market
Loading....

COVID-19 Impact Analysis

COVID-19 pandemic led to government of numerous countries across the globe to impose strict lockdown restrictions during the preliminary stages. In 2023, numerous countries faced the adverse effects of the pandemic due to the outbreak of second wave, which also led governments to again impose lockdown measures. Business shutdowns, partial business operations, and travel restrictions have led to challenges in supply chain and in turn production. However, it is expected that reopening of trade activities, the market will witness steady growth in the demand in the coming years. Impact of COVID-19 on the market demand is considered while estimating the current and forecast market size and growth trends for all the regions and countries.

The report provides a completely separate chapter for COVID-19 Impact Analysis. This chapter includes:

  • Impact Assessment of COVID-19 Pandemic
  • Pre & Post COVID-19 Market Size
  • Qualitative analysis on the short term & long term impact of COVID-19 on the market
  • The analysis provides foremost strategies adopted by competitors to minimize the impact of the pandemic on their business activities and scope for future developments.

Industry Insights

  • The increasing research & development activities for the treatment of Diabetic Macular Edema is likely to accelerate the growth of the Diabetic Macular Edema treatment market during the forecast period.
  • Additionally, advancements in ophthalmic surgery techniques and R&D investment by pharmaceutical companies is further expected to boost the growth of the market in the years to come.
  • The increasing medical costs for the patients and the frequent visits to the physicians is expected to hinder the growth of the market in the years to come.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Real-Time Data Updates:
  • Competitor Benchmarking
  • Market Trends Heatmap
  • Custom Research Queries
  • Market Sentiment Analysis
  • Demographic and Geographic Insights

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Regional Analysis: Preview

Based on region, the Global Diabetic Macular Edema Market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America region led the market with the largest share in 2020. Some of the key countries contributing to the surge in the market are the U.S., U.K., Germany, France, China, India, Japan, and South Korea.

The market comprises of numerous small, medium, and large sized players spread across various geographies. Some of the main competitors in the Global Diabetic Macular Edema Market are Pfizer Inc., Bayer AG, Bausch & Lomb Incorporated, Allergan Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., ShahidBeheshti University of Medical Sciences., Johns Hopkins University, Novartis AG, The National Eye Institute.. The report covers company market share analysis which gives a comprehensive overview of the main competitors in the market. In addition, the report also covers major strategies adopted by market players such as new product launch, acquisitions & mergers, partnerships, collaborations & joint ventures, research & development, and regional expansion. The study also covers the product portfolio of major companies operating in the market.

The Global Diabetic Macular Edema Market can be categorized as Type, Application, End-Use Industry, and Region.

Parameter Details
Segments Covered

By Indication Type

  • diffuse diabetic macular edema
  • focal diabetic macular edema

By Treatment Type

  • anti-VEGF
  • corticosteroids
  • laser photocoagulation therapy
  • other off-label drugs

By Power Consumption

  • intravitreal injections
  • intravitreal implants

By End User

  • hospitals
  • specialty clinics
  • order pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Pfizer Inc.
  • Bayer AG
  • Bausch & Lomb Incorporated
  • Allergan Inc.
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals Inc.
  • ShahidBeheshti University of Medical Sciences.
  • Johns Hopkins University
  • Novartis AG
  • The National Eye Institute.
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis
Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Explore purchase options

FAQ
Frequently Asked Question
  • The global Diabetic Macular Edema valued at USD 4.35 Billion in 2023 and is expected to reach USD 5.61 Billion in 2032 growing at a CAGR of 3.2%.

  • The prominent players in the market are Pfizer Inc., Bayer AG, Bausch & Lomb Incorporated, Allergan Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., ShahidBeheshti University of Medical Sciences., Johns Hopkins University, Novartis AG, The National Eye Institute..

  • The market is project to grow at a CAGR of 3.2% between 2024 and 2032.

  • The driving factors of the Diabetic Macular Edema include

  • XX was the leading regional segment of the Diabetic Macular Edema in 2023.